Current Opinion in Investigational Drugs

30 Current Opinion in Investigational Drugs 2006 Vol 7 No 1
antiparkinsonian agents. For example, data were recently
presented in support of a protective action of rotigotine
whereby the progression of disability was attenuated in those
patients with early-stage PD who received this agent [34].
Conclusion
In conclusion, the area of drug development in PD remains
active and there is realistic hope of new therapies reaching
the market in the short to mid term.
References
1. Johnston TH, Brotchie JM: Drugs in development for Parkinson's
disease. Curr Opin Investig Drugs (2004) 5(7):720-726.
2. Teva Pharmaceutical Ltd: Teva & Lundbeck announce phase III trials
did not demonstrate etilevodopa superiority over standard
levodopa. Press Release (2003):January 06.
www.tevapharm.com/pr/2003/pr_371.asp
3. Pfizer Inc: Pfizer announces the discontinuation of sumanirole
development. Financial Report (2004) July.
www.pfizer.com/pfizer/annualreport/2004/financial/print/r6.pdf
4. Sethy VH, Ellerbrock BR, Wu H: U-95666E: A potential antiparkinsonian
drug with anxiolytic activity. Prog
Neuropsychopharmacol Biol Psychiatry (1997) 21(5):873-883.
5. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc
JL: Limitations of current Parkinson's disease therapy. Ann Neurol
(2003) 53(Suppl 3):S3-S12; discussion S12-S15.
6. DuChane J, Jenkinson C: Changes in quality of life resulting from
treatment for persons with advanced Parkinson's disease:
Sumanirole versus placebo. International Congress on Parkinson's
Disease and Movement Disorders, Miami, FL, USA (2002):P309.
7. Gomez-Mancilla B, Selzer K, Chapman K, Wang M, Simpson S:
Sumanirole is a promising new agent in the treatment of
Parkinson's disease. International Congress on Parkinson's Disease
and Movement Disorders, Miami, FL, USA (2002):P323.
8. Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Kruger J, Jenner
P: The monoamine reuptake blocker brasofensine reverses
akinesia without dyskinesia in MPTP-treated and levodopa-primed
common marmosets. Mov Disord (2002) 17(5):877-886.
9. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P: Dopamine,
but not norepinephrine or serotonin, reuptake inhibition reverses motor
deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
J Pharmacol Exp Ther (2002) 303(3):952-958.
10. Shire Pharmaceuticals Inc: Shire: A focused global pharmaceutical
company. Focusing on a bright future. Annual Review (2003).
www.shire.com/shire/uploads/reports/AR_2003.pdf
11. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P: The
monoamine reuptake inhibitor BTS 74 398 fails to evoke
established dyskinesia but does not synergise with levodopa in
MPTP-treated primates. Mov Disord (2004) 19(1):15-21.
12. Neurosearch Inc: NeuroSearch's partner Boehringer Ingelheim has
concluded the enrollment of patients in three clinical phase II
studies with NS2330 for the treatment of Alzheimer's and
Parkinson's diseases. Annual Report (2004):November 09.
http://neurosearch.com/pub/pdf/20041109_uk.pdf
13. Sepracor Inc: Therapeutic areas: CNS, SEP-226330. Company Web Site
(2005).
http://www.sepracor.com/therap/sep226330.html
14. Prestwick Pharmaceuticals Form S1. FORM S-1 (2005):April 22.
15. GlaxoSmithKline Inc: GlaxoSmithKline announces phase III trial of
controlled release ropinirole. Press Release (2005):April 12.
http://science.gsk.com/pipeline/pipeline-march2005.pdf
16. Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D,
Olanow CW: Double-blind, randomized, controlled trial of rasagiline
as monotherapy in early Parkinson's disease patients. Mov Disord
(2004) 19(8):916-923.
•• This paper describes one of two large studies demonstrating that oncedaily
administration of rasagiline can significantly increase the time during
which patients receive antiparkinsonian benefit from L-DOPA without
troublesome dyskinesia.
17. Lew M, Hauser RA, Hurtig H, Ondo W, Wojcieszek J: Long-term efficacy of
rasagiline in Parkinson's disease. Mov Disord (2005) 20:P250.
•• The second of two large studies demonstrating that once-daily administration of
rasagiline can significantly increase the time during which patients receive
antiparkinsonian benefit from L-DOPA without troublesome dyskinesia.
18. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E:
Rasagiline as an adjunct to levodopa in patients with Parkinson's
disease and motor fluctuations (LARGO, lasting effect in adjunct
therapy with rasagiline given once daily, study): A randomised, doubleblind,
parallel-group trial. Lancet (2005) 365(9463):947-954.
19. Parkinson Study Group: A randomized placebo-controlled trial of
rasagiline in levodopa-treated patients with Parkinson disease and
motor fluctuations: The PRESTO study. Arch Neurol (2005)
62(2):241-248.
20. Mandel S, Weinreb O, Amit T, Youdim MB: Mechanism of
neuroprotective action of the anti-Parkinson drug rasagiline and its
derivatives. Brain Res Brain Res Rev (2005) 48(2):379-387.
21. Hauser RA, Lew M, Hurtig H, Ondo W, Wojcieszek J: Early treatment
with rasagiline is more beneficial than delayed treatment start in
the long-term management of Parkinson's disease. Mov Disord
(2005) 20:P251.
22. Mark MH: Long-term efficacy of istradefylline in patients with
advanced Parkinson's disease. Mov Disord (2005) 20:P310.
23. Kyowa Hakko to focus on biotechnology. Pharma Jpn (2004) 1920: P6.
24. Kyowa Hakko Kogyo Co Ltd: Overseas R&D activities. Company
World Wide Web Site (2004):November 18.
25. Biogen IDEC Inc: Vernalis and Biogen Idec to collaborate on
research for Parkinson's disease. Press Release (2004):June 24.
http://biogen.com/news/BiogenIDECPR_045.htm
26. Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A,
Mouradian MM, Chase TN: Effects of serotonin 5-HT1A agonist in
advanced Parkinson's disease. Mov Disord (2005) 20(8):932-936.
•• This study was the first demonstration in humans that 5HT1A agonists can
reduce L-DOPA-induced dyskinesia, and confirms findings from MPTPlesioned
monkeys.
27. EMD Pharmaceuticals: Sarizotan HCl in patients with Parkinson's
disease suffering from treatment-associated dyskinesia. (2005):August
01.
http://www.clinicaltrials.gov/ct/show/NCT00105508
28. Meco G, Fabrizio E, Epifanio A, Raimondo GD, Vanacore N, Morgante
L: Levetiracetam in L-DOPA-induced dyskinesia. Clin
Neuropharmacol (2005) 28(2):102-103.
29. Michel A, Ravenscroft P, Hill MP, Bezard E, Crossman AR, Klitgaard H:
Seletracetam (UCB 44212) reduces L-DOPA-induced dyskinesia in
the MPTP-lesioned marmoset model of Parkinson's disease. Mov
Disord (2005) 20:S102.
30. Meissner W, Hill MP, Tison F, Gross CE, Bezard E: Neuroprotective
strategies for Parkinson's disease: Conceptual limits of animal models
and clinical trials. Trends Pharmacol Sci (2004) 25(5):249-253.
31. Amgen Inc: Following complete review of phase 2 trial data Amgen
confirms decision to halt GDNF study; Comprehensive review of
scientific findings, patient safety, drove decision. Press Release
(2005):February 11.
http://www.amgen.com/media/media_pr_detail.jsp?year=2005&releaseI
D=673490
32. Lundbeck Inc: Cephalon and Lundbeck announce discontinuation of
CEP-1347 clinical trial in Parkinson's disease. Press Release
(2005):May 11.
http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_158_
EN.asp